SCHEMBL10116262

SCHEMBL10116262

Cc1cc(N2C[C@@H](C)O[C@@H](C)C2)c(C)cc1NC(=O)c1ccc(NS(=O)(=O)C(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 2/20 0.43
CRHR2 Q13324 2/20 0.43
THRB P10828 1/20 0.43
LMNA P02545 2/20 0.41
KDM4E B2RXH2 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MAPT P10636 3/20 0.41
GSK3B P49841 1/20 0.41
ALDH1A1 P00352 3/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
KIF18A Q8NI77 1/20 0.38
KMT2A Q03164 2/20 0.38
SCN9A Q15858 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10133515 1.00 CRHBP (0.43) CRHBPCRHR2THRBLMNAKDM4E
SCHEMBL10116201 0.89 THRB (0.46) CRHBPCRHR2THRBLMNAKDM4E
SCHEMBL10134529 0.88 CRHBP (0.40) CRHBPCRHR2THRBLMNARXFP1
SCHEMBL10116329 0.88 CRHBP (0.40) CRHBPCRHR2THRBLMNARXFP1
SCHEMBL10116207 0.86 MAPT (0.44) CRHBPCRHR2THRBLMNARXFP1
SCHEMBL10134528 0.86 KDM4E (0.43) CRHBPCRHR2THRBLMNAKDM4E
SCHEMBL10116547 0.86 THRB (0.43) CRHBPCRHR2THRBLMNAKDM4E
SCHEMBL13204918 0.86 THRB (0.43) CRHBPCRHR2THRBLMNAKDM4E
SCHEMBL10116325 0.86 KDM4E (0.43) CRHBPCRHR2THRBLMNAKDM4E
SCHEMBL10133544 0.86 THRB (0.43) CRHBPCRHR2THRBLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R CRHBP 238/4885CRHR2 12/4885THRB 414/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R CRHBP 256/4885CRHR2 13/4885THRB 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.